Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2025)

Prime Medicine (PRME) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $58.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 8.05% year-over-year to $58.1 million, compared with a TTM value of $58.1 million through Dec 2025, down 8.05%, and an annual FY2025 reading of $58.1 million, down 8.05% over the prior year.
  • Non-Current Deffered Revenue was $58.1 million for Q4 2025 at Prime Medicine, down from $59.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $63.2 million in Q4 2024 and bottomed at $58.1 million in Q4 2025.